Trial Profile
Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Belatacept (Primary) ; Ciclosporin
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- Acronyms BENEFIT
- Sponsors Bristol-Myers Squibb
- 08 Jun 2022 Results assessing long-term allograft function between belatacept-based regimens and tacrolimus-based regimen up to five years from two clinical studies: BENEFIT and BENEFIT EXT presented at the 2022 American Transplant Congress
- 08 Jun 2022 Results assessing the use of a contemporaneous external control group analysis as a supplement to the BENEFIT study's cyclosporine arm, presented at the 2022 American Transplant Congress.
- 08 Jun 2022 Results assessing the performances of the iBox system to capture this hemodynamic effect to predict long term graft survival in patients under a CNI free regimen in two studies (BENEFIT & BENEFIT EXT) presented at the 2022 American Transplant Congress.